Key result
Growth hormone administration in GH-deficient individuals may induce short-term insulin resistance and impaired fasting glucose, though long-term effects on diabetes risk require further study.
Why the study?
Does growth hormone administration alter glucose metabolism and insulin resistance in humans?
Does growth hormone administration alter glucose metabolism and insulin resistance in humans?
Growth hormone therapy can induce insulin resistance and increase the risk of type 2 diabetes in susceptible individuals, highlighting the need for metabolic monitoring during treatment.
Answers are grounded in this paper and cite their sources.
May warrant glucose monitoring in GH-deficient patients on therapy; leaves open long-term diabetes risk.
Growth hormone (GH) is important for promotion of somatic growth and the regulation of substrate metabolism. Metabolic action of GH occurs in multiple tissues including the liver, muscle, fat and pancreas either directly or indirectly through insulin-like growth factor 1. The diabetogenic action of GH has been well-described in previous in vivo studies. In this paper, we review the metabolic effects of GH on peripheral tissues focusing on glucose metabolism and insulin resistance, and discuss results from human studies on the long-term effects of GH administration on insulin resistance and hyperglycemia.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2017) conducted a review in Growth hormone deficiency. Growth hormone was evaluated. Growth hormone administration in GH-deficient individuals may induce short-term insulin resistance and impaired fasting glucose, though long-term effects on diabetes risk require further study.
Synapse has enriched 10 related papers. Consider them for comparative context: